Pfizer’s COVID Vaccine Sales Plummet 25% Amid New Federal Guidance

Pfizers sales of the COVID-19 vaccine Comirnaty have dropped 25% due to new federal guidance and declining interest in vaccinations, signaling challenges ahead for public health efforts.

COVID-19 vaccine sales for Pfizer fell by 25% in the U.S. as the Centers for Disease Control and Prevention narrowed its recommendations on vaccination eligibility.
The approval of the updated Pfizer–BioNTech COVID-19 vaccine occurred later than usual, contributing to the decrease in sales as the fall vaccination season begins.
Experts attribute the decline in interest to ongoing vaccine hesitancy among Americans, who are increasingly less motivated to receive the COVID-19 vaccine ahead of potential winter surges.

Why It Matters

This decline in sales reflects a growing trend of vaccine hesitancy that could hinder efforts to control future COVID-19 outbreaks. Understanding public attitudes towards vaccinations is crucial for strategic public health planning and response.